DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20174989

Fetal outcome of HIV positive pregnant women taking highly active antiretroviral therapy at Yaoundé Central Hospital: a cross sectional analytic study

Fouedjio J. H., Loweh Limyuy Ntani, Fouelifack Ymélé Florent, Mbu Robinson Mbu Robinson Enow

Abstract


Background: HIV infection in pregnant women is delicate both for the mother and her child. With the adoption of option B+ treatment plan by Cameroon’s ministry of public health, there has been a marked decrease in the vertical transmission of HIV from mothers to their babies. There is a dearth of evidence in sub-Saharan Africa, especially in Cameroon, on the effects of highly active antiretroviral therapy (HAART) on pregnancy and foetal outcomes with respect to the time from onset of treatment. We therefore carried out this study to determine the foetal outcome of women on HAART. We hypothesized that the foetal outcome is poorer for pregnant women starting HAART during pregnancy compared to those starting HAART prior to conception.

Methods: We carried out an analytic cross-sectional study which spanned from the 1st February to 30th April 2017 at the Yaoundé Central Maternity. We included consenting hospitalised HIV infected women who just terminated a pregnancy (abortion or delivery), and who started HAART at least four weeks before termination of pregnancy. Data was analysed using EPI info 7.2.1.0. SPSS version 20.0. Odds ratio (OR) was used to assess the degree of association that could exist between qualitative variables. The threshold of statistical significance was set at a p-value of 0.05.

Results: A total of 121 participants were recruited in the present study. The mean age of the participants was 31.3±5.3 years for those who started HAART before pregnancy and 29.4±5.5 years for those who started during pregnancy (p=0.07). The viral loads means for those who started taking HAART before pregnancy 34.6±21.5 cells/mm3 and those who started during pregnancy 60±14 cells/mm3 (p = 0.01). Overall there were not any significant adverse fetal outcomes caused by taking HAART before or during pregnancy (p >0.05).

Conclusions: Despite the fact that the viral load was more elevated in women starting HAART prior pregnancy compared to those started during pregnancy, there was no significant adverse foetal outcome related to time of initiation of HAART treatment by pregnant HIV positive in Yaoundé central Maternity. We suggest that the implementing of the test and treat strategy will have a positive impact on the vertical transmission of HIV.


Keywords


Fetal outcome, HAART, HIV

Full Text:

PDF

References


Global Statistics. The Global HIV/AIDS Epidemic. Available at https://www.aids.gov/hiv-aids-basics/hiv-aids-101/global-statistics/ cited 2016 Dec 22.

UNAIDS. Fact sheet November 2016. Available at http://www.unaids.org/en/resources/fact-sheet cited 2016 Dec 22

Global AIDS update 2016. Global AIDS update. Available at http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf cited 2016 Dec 2.

Machado ES, Hofer CB, Costa TT, Nogueira SA, Oliveira RH, Abreu TF, et al. Pregnancy outcome in HIV-1-infected women receiving combination antiretroviral therapy prior versus after conception. Sex Transm Infect. 2009;85(2):82-7.

Mesmey E, Liliane E, Anastasie M, de Dieu MJ, Arlette M, Emilienne N, et al. Towards elimination of mother-to-child transmission of HIV on the horizon 2015. Progress report PMTCT-Cameroon. 2015. Available at http://www.cnls.cm/docs/Rapport_de_Progr%C3%A8s_PTME_2014_final.pdf

Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, et al. Antiretroviral treatment and prevention of peripartum and postnatal hiv transmission in West Africa: evaluation of a two-tiered approach. PLoS Med. 2007;4(8).

Global report on AIDS statistics, information and facts about HIV AIDS, Global Events, USA, Europe, Middle East, Asia Pacific. Available at http://hiv-aids-std.conferenceseries.com/events-list/global-report-on-aids-statistics-information-and-facts-about-hiv-aids [cited 2016 Dec 2].

Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-Infected Women in Botswana. J Infect Dis. 2012;206(11):1695-705.

van der Merwe K, Hoffman R, Black V, Chersich M, Coovadia A, Rees H. Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. J Int AIDS Soc. 2011;14:42.

Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A. The next generation of the World Health Organization’s global antiretroviral guidance. J Int AIDS Soc. 2013;16(1).

WHO. Antiretroviral therapy (ART) coverage among all age groups. WHO. Available at http://www.who.int/gho/hiv/epidemic_response/ART_text/en/ [cited 2016 Dec 2].

Njim T, Atashili J, Mbu R, Choukem SP. Low birth weight in a sub-urban area of Cameroon: an analysis of the clinical cut-off, incidence, predictors and complications. BMC Pregnancy Childbirth. 2015;15:288.

Bogart LM, Chetty S, Giddy J, Sypek A, Sticklor L, Walensky RP, et al. Barriers to care among people living with HIV in South Africa: contrasts between patient and healthcare provider perspectives. AIDS Care. 2013;25(7):843-53.

Ross CE, Mirowsky J. The Interaction of personal and parental education on health. Soc Sci Med. 2011;72(4):591-9.

Baker DP, Leon J, Greenaway EG, Collins J, Movit M. The Education Effect on Population Health: a reassessment. Popul Dev Rev. 2011;37(2):307-32.

Ngemu EK, Khayeka-Wandabwa C, Kweka EJ, Choge JK, Anino E, Oyoo-Okoth E. Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women. BMC Res Notes. 2014;7:52.

Glenwe P, Karthik. Improving school education outcomes in developing countries: Evidence, knowledge gaps, and policy implications. Available at http://www.bsg.ox.ac.uk/sites/www.bsg.ox.ac.uk/files/documents/RISE_WP-001_Glewwe_Muralidharan.pdf cited on 2017 May 31

Erb P, Battegay M, Zimmerli W, Rickenbach M, Egger M. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. Arch Intern Med. 2000;160(8):1134-40.

Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001;286(20):2560-7.

Franke MF, Spiegelman D, Ezeamama A, Aboud S, Msamanga GI, Mehta S, et al. Malaria Parasitemia and CD4 T cell count, viral load, and adverse hiv outcomes among HIV-infected pregnant women in Tanzania. Am J Trop Med Hyg. 2010;82(4):556-62.

Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d’Ivoire. AIDS Lond Engl. 2008;22(14):1815-20.

Walli R, Herfort O, Michl GM, Demant T, Jäger H, Dieterle C, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS Lond Engl. 1998;12(15):F167-73.

Kebede B, Andargie G, Gebeyehu A. Birth outcome and correlates of low birth weight and preterm delivery among infants born to HIV-infected women in public hospitals of Northwest Ethiopia. Health (NY). 2013;05(07):25.

Chiu IM, Yaniv A, Dahlberg JE, Gazit A, Skuntz SF, Tronick SR, et al. Nucleotide sequence evidence for relationship of AIDS retrovirus to lentiviruses. Nature. 1985;317(6035):366-8.

Wiley: Sampling Techniques, 3rd Edition - William G. Cochran. Available at http://eu.wiley.com/WileyCDA/WileyTitle/productCd-047116240X.html cited on 2016 Dec 1.

Grosch-Woerner I, Puch K, Maier RF, Niehues T, Notheis G, Patel D, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med. 2008;9(1):6-13.

Marazzi MC, Palombi L, Nielsen-Saines K, Haswell J, Zimba I, Magid NA, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS Lond Engl. 2011;25(13):1611-8.

Cotter AM, Garcia AG, Duthely ML, Luke B, O’Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?. J Infect Dis. 2006;193(9):1195-201.

Ahmed S, Kim MH, Abrams EJ. Risks and benefits of lifelong antiretroviral treatment for pregnant and breastfeeding women: a review of the evidence for the Option B+ approach. Curr Opin HIV AIDS. 2013;8(5):474-89.

Watts DH, Mofenson LM. Antiretrovirals in pregnancy: a note of caution. J Infect Dis. 2012;206(11):1639.